These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 18675097

  • 1. Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results.
    Masetti M, Rompianesi G, Montalti R, Romano A, Spaggiari M, Ballarin R, Guerrini GP, Gerunda GE.
    Transplant Proc; 2008; 40(6):1947-9. PubMed ID: 18675097
    [Abstract] [Full Text] [Related]

  • 2. Sirolimus interferes with iron homeostasis in renal transplant recipients.
    Maiorano A, Stallone G, Schena A, Infante B, Pontrelli P, Schena FP, Grandaliano G.
    Transplantation; 2006 Oct 15; 82(7):908-12. PubMed ID: 17038905
    [Abstract] [Full Text] [Related]

  • 3. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R.
    Clin Transplant; 2007 Oct 15; 21(4):536-43. PubMed ID: 17645716
    [Abstract] [Full Text] [Related]

  • 4. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

  • 5. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 6. Everolimus plus dosage reduction of cyclosporine in cardiac transplant recipients with chronic kidney disease: a two-year follow-up study.
    Fuchs U, Zittermann A, Hakim-Meibodi K, Börgermann J, Schulz U, Gummert JF.
    Transplant Proc; 2011 Jun 15; 43(5):1839-46. PubMed ID: 21693287
    [Abstract] [Full Text] [Related]

  • 7. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
    Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L.
    Liver Transpl; 2006 Nov 15; 12(11):1640-8. PubMed ID: 16598777
    [Abstract] [Full Text] [Related]

  • 8. Higher incidence of acute rejection in renal transplant recipients with low everolimus exposure.
    Romagnoli J, Citterio F, Favi E, Salerno MP, Tondolo V, Spagnoletti G, Renna R, Castagneto M.
    Transplant Proc; 2007 Nov 15; 39(6):1823-6. PubMed ID: 17692622
    [Abstract] [Full Text] [Related]

  • 9. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients.
    Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Barrientos A.
    Transplant Proc; 2007 Sep 15; 39(7):2242-4. PubMed ID: 17889151
    [Abstract] [Full Text] [Related]

  • 10. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
    Wang CH, Chou NK, Wu FL, Ko WJ, Tsao CI, Chi NH, Hsu RB, Wang SS.
    Transplant Proc; 2006 Sep 15; 38(7):2032-4. PubMed ID: 16979990
    [Abstract] [Full Text] [Related]

  • 11. Indications and management of everolimus after liver transplantation.
    Bilbao I, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L, Caralt M, Blanco L, Gantxegi A, Margarit C, Charco R.
    Transplant Proc; 2009 Sep 15; 41(6):2172-6. PubMed ID: 19715864
    [Abstract] [Full Text] [Related]

  • 12. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
    Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T, 2306 and 2307 study groups.
    Transpl Int; 2007 Jan 15; 20(1):27-36. PubMed ID: 17181650
    [Abstract] [Full Text] [Related]

  • 13. Severe sirolimus-related inflammatory state anemia in an HIV+ liver transplant patient with calcineurin inhibitor renal insufficiency: a case report.
    Moreno A, Bárcena R, García-Gonzalez M, García-Hoz F, Quereda C, Casado JL, Pérez-Elías MJ, Fortún J, Nuño J, Arranz I, Moreno S.
    Transplant Proc; 2008 Dec 15; 40(10):3810-2. PubMed ID: 19100499
    [Abstract] [Full Text] [Related]

  • 14. mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study.
    Moro J, Almenar L, Martínez-Dolz L, Izquierdo M, Rueda J, Arnau MA, Agüero J, Sánchez-Lázaro I, Ortiz V, Salvador A.
    Transplant Proc; 2007 Sep 15; 39(7):2365-7. PubMed ID: 17889191
    [Abstract] [Full Text] [Related]

  • 15. Prevalence of anemia in renal transplant patients: results from MOST, an observational trial.
    Fernández Fresnedo G, Palomar R, Rodrigo E, Ruiz JC, de Francisco AL, Cotorruelo JG, Arias M.
    Transplant Proc; 2005 Nov 15; 37(9):3821-2. PubMed ID: 16386550
    [Abstract] [Full Text] [Related]

  • 16. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis.
    Loriga G, Ciccarese M, Pala PG, Satta RP, Fanelli V, Manca ML, Serra G, Dessole P, Cossu M.
    Transplant Proc; 2010 May 15; 42(4):1297-302. PubMed ID: 20534285
    [Abstract] [Full Text] [Related]

  • 17. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function.
    Friend P, Russ G, Oberbauer R, Murgia MG, Tufveson G, Chapman J, Blancho G, Mota A, Grandaliano G, Campistol JM, Brault Y, Burke JT, Rapamune Maintenance Regimen (RMR) Study Group.
    Transpl Int; 2007 Sep 15; 20(9):754-60. PubMed ID: 17565578
    [Abstract] [Full Text] [Related]

  • 18. South American Heart Transplantation Registry of patients receiving everolimus in their immunosuppressive regimens.
    Bortman GV, Ceruti B, Ahualli L, Colque R, Amuchástegui M, Sgrosso JL, Muñoz J, Vulcano N, Burgos C, Diez F, Rodriguez MC, Perrone SV.
    Transplant Proc; 2010 Sep 15; 42(1):324-7. PubMed ID: 20172342
    [Abstract] [Full Text] [Related]

  • 19. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.
    Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V.
    J Hypertens; 2008 Nov 15; 26(11):2213-9. PubMed ID: 18854763
    [Abstract] [Full Text] [Related]

  • 20. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function.
    De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E, Ducci J, Caneschi F, Coletti L, Campani D, Filipponi F.
    Transpl Int; 2009 Mar 15; 22(3):279-86. PubMed ID: 19054383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.